Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.

Blood Adv · 2023 · PMC10424141 · PMID 37163361

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the unweighted analysis, TTNTD was NR for either cohort, although the ATT-weighted analysis showed a trend favoring acalabrutinib.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

This trend favoring acalabrutinib did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.